Chao Wang

Chao Wang is a highly experienced scientist with a robust background in drug discovery and neurodegenerative disease research. Currently serving as Principal Scientist at Verge Genomics since February 2021, Chao Wang has previously held positions including Associate Principal Scientist and Scientist focused on drug discovery. At Aeton Therapeutics, from October 2018 to January 2021, Chao Wang developed humanized anti-acetylated tau antibodies for Alzheimer’s disease treatment. Chao Wang's extensive research at Gladstone Institutes spanned over nine years, concentrating on neuroinflammation and tau pathology, while the postdoctoral fellowship involved multiple aspects of Alzheimer’s research. Chao Wang earned a PhD in Molecular and Biochemical Nutrition from the University of California, Berkeley, where thesis research focused on retinoic acid metabolism. Early academic training at the University of Science and Technology of China culminated in a Bachelor of Science in Biological Sciences. Proficient in various laboratory techniques, Chao Wang contributes significantly to the field of neurobiology and therapeutic development.